Thematics Asset Management Acquires 1,038 Shares of Thermo Fisher Scientific Inc. $TMO

Thematics Asset Management raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 51,837 shares of the medical research company’s stock after buying an additional 1,038 shares during the period. Thematics Asset Management’s holdings in Thermo Fisher Scientific were worth $21,018,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Mondrian Investment Partners LTD increased its holdings in Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after purchasing an additional 127,357 shares during the period. TIAA Trust National Association increased its stake in shares of Thermo Fisher Scientific by 10.5% during the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after buying an additional 11,817 shares during the period. Caledonia Investments PLC raised its holdings in shares of Thermo Fisher Scientific by 11.5% in the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock valued at $45,299,000 after acquiring an additional 11,500 shares in the last quarter. Heritage Investors Management Corp lifted its stake in Thermo Fisher Scientific by 9.6% in the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock worth $22,944,000 after acquiring an additional 4,971 shares during the period. Finally, LBP AM SA increased its position in Thermo Fisher Scientific by 13.4% during the 2nd quarter. LBP AM SA now owns 261,038 shares of the medical research company’s stock valued at $105,840,000 after purchasing an additional 30,837 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.5%

Shares of TMO stock opened at $572.49 on Monday. The stock’s fifty day moving average price is $559.70 and its 200 day moving average price is $486.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a market cap of $215.09 billion, a price-to-earnings ratio of 33.07, a price-to-earnings-growth ratio of 4.19 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock repurchase plan on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 22,046 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares of the company’s stock, valued at $47,404,976.52. The trade was a 20.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 7,250 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at $64,400,668.20. This trade represents a 5.99% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 149,271 shares of company stock valued at $86,507,282. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TMO. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Barclays raised their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Finally, Leerink Partners boosted their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $609.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.